FDA Approves New Drug for Advanced Prostate Cancer
The U.S. Food and Drug Administration has approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.
Updated Tool Now Available to Predict Prostate Cancer Spread
Prostate cancer experts at Johns Hopkins Hospital in Baltimore, MD, have developed an updated version of the Partin Tables, a tool to help men diagnosed with prostate cancer and their doctors to better assess their chance of a surgical cure. The updated tool is published in the British Journal of Urology International. This represents the third update of the data.
What You Need to Know about Urinary Incontinence after Prostate Cancer Treatment
by Jeffrey Albaugh, PhD, APM, CUCNS
Men treated for prostate cancer know that when the catheter comes out, the leakage may begin. For many men, this leakage may resolve over the next year, but for some men, the issue may last longer. Research reveals approximately 15 percent of men are incontinent up to one year following either radical prostatectomy or laparoscopic prostatectomy. It can take as long as two years for men to regain urinary continence.
Exploring Your Treatment Options for Prostate Cancer
Men with prostate cancer have many treatment options. These options include active surveillance, surgery, radiation therapy, hormone therapy, chemotherapy, and immunotherapy. You may receive more than one type of treatment.
Above-the-Belt Relationship Changes That Can Come with Prostate Cancer
by Arnold Melman, MD, and Rosemary E. Newnham
Although many men see their temporary or permanent loss of erectile function as the chief change that affects their relationships post-treatment, most researchers would argue that the bigger changes happen – and need to happen – above the belt buckle: in the brain and in the heart.
FDA Expands Zytiga’s Use for Late-stage Prostate Cancer
The U.S. Food and Drug Administration has expanded the approved use of Zytiga® (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy.
Prostate Cancer Affects Women, Too
by Cindie Hubiak
Our society considers prostate cancer solely a man’s disease. It’s not. Prostate cancer can affect women physically, emotionally, and spiritually. To complicate matters further, many men don’t want anyone to know about their diagnosis and treatment. This vow of silence reduces potential resources for women, pushing the topic under a rug, causing many of us to feel suffocated and isolated.
Navigating the Road to Recovery
Recovery from prostate cancer treatment is different for everyone. Once you have selected your treatment option, talk with other prostate cancer survivors who can help you understand what you can expect during your recovery process. Remember to include physician specialists, supportive family members, and friends who can provide various levels of support during your treatment and recovery.